v3.26.1
Related Party - Gilead Sciences, Inc. (Details)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
shares
Jun. 30, 2026
USD ($)
member
Jun. 30, 2025
USD ($)
Dec. 31, 2023
USD ($)
program
Dec. 31, 2021
USD ($)
program
Dec. 31, 2020
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Related Party Transaction [Line Items]                    
Sale of stock, consideration received on transaction     $ 150              
Number of programs, eligible to receive regulatory and commercial milestone payments | program           4        
Revenue recognized from amounts in deferred revenue at the beginning of the period $ 35 $ 160   $ 52 $ 188          
Accounts payable, current $ 34     $ 34         $ 42  
Gilead                    
Related Party Transaction [Line Items]                    
Sale of stock, consideration received on transaction     $ 15              
Gilead                    
Related Party Transaction [Line Items]                    
Sale of stock, number of shares acquired in transaction (in shares) | shares     1.4              
Related Party                    
Related Party Transaction [Line Items]                    
Percentage of outstanding common stock held 24.70%     24.70%            
Accounts payable, current $ 12     $ 12         $ 24  
Related Party | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense                    
Related Party Transaction [Line Items]                    
Reimbursement from related party for shared costs 2 13   $ 2 8          
Purchase Agreement | Related Party                    
Related Party Transaction [Line Items]                    
Number of board members | member       3            
Gilead Collaboration Agreement                    
Related Party Transaction [Line Items]                    
Option payment upon completion of certain IND-enabling activities             $ 60      
Option payment upon achievement of certain development milestones             150      
Gilead Collaboration Agreement | Related Party                    
Related Party Transaction [Line Items]                    
Upfront cash payment               $ 175    
Collaboration term for current and future clinical programs               10 years    
Option continuation payment due upon second anniversary of agreement               $ 100    
Option continuation payment due upon fourth anniversary of agreement               100   $ 100
Option continuation payment due upon sixth anniversary of agreement               100    
Option continuation payment due upon eighth anniversary of agreement               100    
Option fee per program for all other programs entering clinical development to exercise option               $ 150    
Revenue recognized from amounts in deferred revenue at the beginning of the period $ 33 $ 160   $ 48 $ 188          
Gilead Collaboration Agreement | Related Party | Maximum                    
Related Party Transaction [Line Items]                    
Potential regulatory approval milestones payment receivable related to domvanalimab             $ 500      
Amended Gilead Collaboration Agreement                    
Related Party Transaction [Line Items]                    
Number of exercise option to programs | program             3      
Option payments received             $ 725      
Removal of option continuation payment under agreement             $ 100      
Option payment upon achievement of certain development milestones           $ 150        
Amended Gilead Collaboration Agreement | Related Party                    
Related Party Transaction [Line Items]                    
Option payment upon completion of certain IND-enabling activities           45        
Total upfront cash payment           $ 35        
Number of research programs | program           2        
Amended Gilead Collaboration Agreement | Related Party | Maximum                    
Related Party Transaction [Line Items]                    
Regulatory and commercial milestone payments received           $ 375